Terns Pharmaceuticals, Inc.
TERN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20 | $20 | $19 | $18 |
| G&A Expenses | $8 | $7 | $9 | $8 |
| SG&A Expenses | $8 | $7 | $9 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $28 | $27 | $27 | $26 |
| Operating Income | -$28 | -$27 | -$27 | -$26 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $3 | $4 | $4 |
| Pre-Tax Income | -$25 | -$24 | -$24 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$24 | -$24 | -$22 |
| % Margin | – | – | – | – |
| EPS | -0.27 | -0.26 | -0.26 | -0.24 |
| % Growth | -3.8% | 0% | -8.3% | – |
| EPS Diluted | -0.27 | -0.26 | -0.26 | -0.24 |
| Weighted Avg Shares Out | 92 | 92 | 91 | 91 |
| Weighted Avg Shares Out Dil | 92 | 92 | 91 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $4 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$24 | -$27 | -$26 |
| % Margin | – | – | – | – |